AMGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Amgen Inc (AMGN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive growth trends, and stable technical indicators make it a solid choice for long-term investment. While there are no immediate trading signals or major catalysts, the company's robust fundamentals and analyst confidence support a buy decision.
The MACD is positive and contracting, indicating a bullish trend. RSI is neutral at 58.661, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 375.223, with resistance at 385.071 and support at 365.375.
Additionally, Amgen's pipeline progress in Phase II and III trials for key treatments adds long-term growth potential.
The stock experienced a 1.30% decline in the regular market session and a 0.43% drop post-market. Barclays initiated coverage with a cautious Equal Weight rating, citing uncertainties around the Phase 3 MARITIME readout. Loss of exclusivity (LOE) remains a concern for some analysts.
Amgen reported strong Q4 2025 financials with revenue of $9.87 billion (+8.58% YoY), net income of $1.33 billion (+112.60% YoY), and EPS of $2.46 (+112.07% YoY). Gross margin improved to 72.88% (+10.84% YoY), reflecting efficient cost management and profitability.
Analyst sentiment is mixed but leans positive. Recent upgrades include Piper Sandler raising the price target to $432 with an Overweight rating and TD Cowen increasing the target to $420 with a Buy rating. However, some firms like Barclays and Freedom Capital remain cautious with Equal Weight or Hold ratings, citing valuation concerns and LOE risks.
